Hosted on MSN2mon
Cofactor’s cancer biomarker test outshines standard ICI predictive tests
Cofactor said that current methods used to predict patient responses to ICIs like measuring PD-L1 combined positive score (CPS) and tumour mutational burden (TMB) are not effective. Both scores ...
Targeted Oncology11d
Five-Year Data Confirm Benefit of Nivolumab in Upper GI Cancer
David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...
pharmaphorum2y
Opdivo backed by NICE for rare gastro-oesophageal cancers
or oesophageal adenocarcinoma tumours that express PD-L1 with a combined positive score (CPS) of 5 or more. The decision extends the range of patients with these forms of gastro-oesophageal cancer ...
Pharmabiz1d
CStone Pharma announces inclusion of Cejemly as a first-line combination therapy for NSCLC in ESMO guideline
In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...
Cstone Announces Inclusion Of Cejemly® (Sugemalimab) As A First-Line Combination Therapy For NSCLC In ESMO Guideline
The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...